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Abstract
Background: Gene silencing due to aberrant DNA methylation is a frequent event in hepatocellular carcinoma (HCC) and
also in hepatocellular adenoma (HCA). However, very little is known about epigenetic defects in fibrolamellar carcinoma
(FLC), a rare variant of hepatocellular carcinoma that displays distinct clinical and morphological features.
Methodology/Principal Findings: We analyzed the methylation status of the APC, CDH1, cyclinD2, GSTp1, hsa-mir-9-1, hsa-
mir-9-2, and RASSF1A gene in a series of 15 FLC and paired normal liver tissue specimens by quantitative high-resolution
pyrosequencing. Results were compared with common HCC arising in non-cirrhotic liver (n=10). Frequent aberrant
hypermethylation was found for the cyclinD2 (19%) and the RASSF1A (38%) gene as well as for the microRNA genes mir-9-1
(13%) and mir-9-2 (33%). In contrast to common HCC the APC and CDH1 (E-cadherin) genes were found devoid of any DNA
methylation in FLC, whereas the GSTp1 gene showed comparable DNA methylation in tumor and surrounding tissue at a
moderate level. Changes in global DNA methylation level were measured by analyzing methylation status of the highly
repetitive LINE-1 sequences. No evidence of global hypomethylation could be found in FLCs, whereas HCCs without
cirrhosis showed a significant reduction in global methylation level as described previously.
Conclusions: FLCs display frequent and distinct gene-specific hypermethylation in the absence of significant global
hypomethylation indicating that these two epigenetic aberrations are induced by different pathways and that full-blown
malignancy can develop in the absence of global loss of DNA methylation. Only quantitative DNA methylation detection
methodology was able to identify these differences.
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Introduction
Inactivation of tumor suppressor genes by aberrant methylation
of cytosine residues in the promoter region is an important
molecular alteration contributing to the development and
progression of malignant tumors [1]. It can already be found in
pre-malignant lesions and in-situ carcinomas indicating that this
epigenetic alteration is an early event in carcinogenesis [2]. In
colonic carcinoma acquired genetic and epigenetic defects
complement one another in the process of malignant transforma-
tion [3]. The diagnostic and prognostic potential of altered DNA
methylation patterns is currently being unraveled [4].
Aberrant DNA methylation is a well described phenomenon in
common hepatocellular carcinoma [5] and also in hepatocellular
adenoma [6]. However, very little is known about epigenetic defects
in fibrolamellar carcinoma (FLC), a rare variant of hepatocellular
carcinoma that displays unique clinical and morphologicall features
[7,8]. FLC occurs in the absence of chronic liver disease in children
and young adults and is characterized by large eosinophilic tumor
cells and abundant deposition of collagen between tumor cells
(Figure 1). The few existing studies of genetic defects in FLCs
indicate that chromosomal instability is a rare event in FLCs and
that mutations frequently found in common HCC (e.g., in the TP53
or the CTNNB1 gene) occur at a much lower frequency if at all
[9,10]. We performed epigenetic profiling of a series of FLCs
(n=15) in comparison to common HCC arising in non-cirrhotic
livers. For this purpose the global methylation level as well as gene-
specific hypermethylation at 7 loci was assessed using quantitative
pyrosequencing methodology.
Results
Selection of patients and genes under study
Upon review 15 cases of FLC were identified from the archives
of the Institute of Pathology, Medizinische Hochschule Hannover.
10 cases of common HCC arising in non-cirrhotic livers were used
as a control group (Figure 1). Patient age, sex and tumor stage are
summarized in Table 1.
The methylation status of the following loci was analyzed in a
series of 15 FLC samples and the surrounding normal appearing
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technology: APC, CDH1, cyclinD2, ESR1, GSTp1, LINE-1,
MINT31, hsa-mir-9-1, hsa-mir-9-2, RASSF1A, SFRP1, SOCS-1. With
the exception of the microRNA genes these loci are reported to be
frequently hypermethylated in common hepatocellular carcinoma
in more than one study (see [5] and references therein). Common
HCC was chosen as a reference because HCC and FLC are
regarded as to arise not only in the same organ but also in the very
same cell type. Aberrant hypermethylation of microRNA genes
hsa-mir-9-1 and hsa-mir-9-2 in liver tumors has been recently
Figure 1. Representative histology of FLC and common HCC without cirrhosis. Representative histology of fibrolamellar carcinoma (A) and
common hepatocellular carcinoma in non-cirrhotic liver (B). FLCs show large eosinpphilic tumor cells containing cytoplasmic globuli (arrow). There
are abundant collagenous bands (arrowheads) separating nests of tumor cells. HCC of common type show solid nests and trabecules of smaller and
paler cells without formation of collagenous bands (HE stained, original magnification A): 2006, B): 1006).
doi:10.1371/journal.pone.0013688.g001
Table 1. Overview of patients.
FLC cases
no. sex age UICC-classification Vascular invasion AFIP Grade HBV HCV
1 male 26 pT4, pN1 neg. n/a
2 male 20 pT3, pN1 present neg. neg.
3 male 20 pT4, pN1, pM1 present neg. neg.
4 male 39 pT1, pN0 absent n/a n/a
5 male 19 pT2, pNx present neg. neg.
6 male 24 pT3, pN1, pM1 present neg. neg.
7 female 15 pT4, pN1 neg. neg.
8 female 32 pT1, pNx absent neg. neg.
9 male 19 pT3, pN1 present neg. neg.
10 female 28 pT1, pNx absent n/a n/a
11 female 13 pT3, pN0, pM1 present neg. neg.
12 male 28 pT3, pN1, pM1 present neg. neg.
13 female 36 pT1, pN0 absent HBV+ neg.
14 female 13 pT1, pNx absent neg. neg.
15 male 22 pT1, pN0 absent neg. neg.
Common HCC without cirrhosis
1 male 82 pT3, pNx present G3 n/a n/a
2 female 80 pT2, pNx present G2 neg. neg.
3 female 66 pT2, pN0 present G2 n/a n/a
4 female 69 pT1, pN0 absent G3 neg. neg.
5 male 67 pT1, pNx absent G2 neg. neg.
6 male 84 pT3, pNx present G3 neg. neg.
7 male 58 recurrence neg. neg.
8 male 61 pT2, pNx present G2 neg. neg.
9 male 61 pT2, pNx present G2 neg. neg.
10 male 78 pT1, pNx absent G2 neg. HCV+
doi:10.1371/journal.pone.0013688.t001
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Gen-specific hypermethylation very often takes place in the
context of a generalized hypomethylation ([11] and the methyla-
tion status of the highly repetitive LINE-1 sequence is a suitable
surrogate marker for assessing this global loss of methylation [12].
Therefore, methylation analysis of LINE-1 was included.
Since fibrolamellar carcinoma is a rare subtype of liver
carcinoma [7], several specimens were quite old (up to 20 years)
and collected under non-standardized conditions. Therefore, yield
and quality of genomic DNA extracted from the paraffin blocks
was highly variable within this series and for several loci only a
subset of samples gave reproducible results. For these reasons, the
further analysis and discussion focus on the following loci: APC,
CDH1, cyclinD2, GSTp1, LINE-1, hsa-mir-9-1, hsa-mir-9-2, and
RASSF1A.
For these 8 loci high-quality pyrosequencing data could be
obtained for all specimens with only very few exceptions: The
results of 399 out of 400 measurements (99.8%) are summarized in
Figures 2 and 3.
Definition of ‘‘hypermethylation’’
DNA methylation levels for all genes under study displayed a
quite high variation in the non-tumorous adjacent tissue. The
range of variation ranged from 6 percentage points for the CDH1
(E-cadherin) gene (2–8%) to up to 49% percentage points for
GSTp1 gene (7–56%). Therefore, two different definitions for
scoring a tumor sample as ‘‘hypermethylated’’ were applied:
a) ‘‘hypermethylated’’ is defined by levels in excess of two
standard deviations above the mean of the control group of
adjacent non-tumorous liver tissue (‘‘mean of control group +26
standard deviation’’, [6]).
b) ‘‘hypermethylated’’ is defined by levels of methylation 50%
higher than in the corresponding non-neoplastic liver tissue from
the same patient. In order to avoid over-interpretation of data due
to background fluctuations (e.g., comparing 6% in the tumor
fraction with 3.5% in the adjacent normal tissue fraction) only
those samples were scored ‘‘hypermethylated’’ in which the
methylation level in the tumor fraction were above 10%.
Definition a) is much more stringent, because the above
mentioned high variation in the control group of normal
appearing adjacent non-tumorous specimens causes a high
standard deviation and thereby a high threshold value. For this
reason, this threshold setting may conceal significant differences
between normal and tumor for individual cases. For example,
methylation level of the cyclinD2 gene in the tumor fraction of FLC
15 is 18.8%, in the surrounding normal tissue only 5.7%. Both
values are below the threshold defined following definition a)
(27.8% for cyclinD2 in FLC) but are clearly indicating increased
DNA methylation in the tumor tissue (with statistical significance).
For a detailed comparison of the results using both definitions
see Figure S1.
Hypermethylation of cyclinD2 and RASSF1A in FLC
Aberrant hypermethylation of the cyclinD2 and the RASSF1A
gene has been described for common hepatocellular carcinoma
arising in cirrhotic liver tissue [13] as well as in many other
carcinomas, including breast, gastric, and colon carcinoma [14].
Figure 2. Summary of methylation data for FLC and HCC without cirrhosis. Frequent aberrant hypermethylation in FLC is obvious. A black
box indicates ‘‘hypermethylated’’ according to the stringent threshold definition (mean of the control group plus 26STD, see text for details).
doi:10.1371/journal.pone.0013688.g002
DNA Methylation in FLC
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13688In fibrolamellar carcinoma these two genes are also frequent
targets of aberrant hypermethylation. Both genes were found to be
hypermethylated in 2/15 (13.3%) and 5/15 (33.3%) of FLC cases,
respectively. There were no statistical significant differences in
comparison to the control group of common HCC (cyclinD2: 4/10,
RASSF1A: 6/10, p=0.18 and 0.24, respectively, Fisher’s exact test,
two-sided).
Hypermethylation of microRNA genes hsa-mir-9-1 and
hsa-mir-9-2 in FLC
Aberrant hypermethylation of microRNA genes has been
reported for several human malignancies, including colon cancer
[15], breast cancer [16], acute lymphoblastic leukemia [17], and
chronic myelogenous leukemia [18]. So far, only two studies
reported microRNA gene hypermethylation in liver tumors:
according to Datta et al., 2 out of 4 HCC specimens tested showed
hypermethylation of the hsa-mir-1 gene [19]. In a more comprehen-
sive study, Furuta et al. could demonstrate aberrant methylation of
microRNA genes miR-124, miR-203,a n dmiR-375 in a series of 41
common hepatocellular carcinoma cases [20]. Our own systematic
study of a range of liver tumors including fibrolamellar carcinoma
identified several frequently hypermethylated microRNA genes
(Albat and Lehmann, in preparation). In FLC, hsa-mir-9-1 is
hypermethylated in 3/15 cases (20%), in HCC without cirrhosis in
6/10 cases (60%). Hsa-mir-9-2 is hypermethylated in 6/15 cases
(40%)inFLCandin6/10cases(60%)inHCCwithoutcirrhosis.For
both microRNA genes there are no significant differences in
hypermethylationbetweenFLCandHCCwithoutcirrhosis(Fisher’s
exact test, two-sided, p=0.087 and 0.43, respectively) and the
hypermethylation in both entities is quite frequent (20 to 60%).
Absence of APC, CDH1, and GSTp1 gene
hypermethylation in FLC
All specimens from patients with FLC (tumor and adjacent
normal tissue) showed only little or no methylation in the APC and
the CDH1 promoter not qualifying for hypermethylation status
according to the definitions outlined above.
On the contrary, 3 samples showed a clear reduction of the
methylation levels of the APC gene in FLC compared to adjacent
non-neoplastic tissue from the same patient.
The GSTp1 gene showed variable methylation levels in the FLC
specimens (15–50%) but to a very similar extent in nearly all
samples of surrounding normal liver tissue (10–55%). Therefore,
following the stringent threshold defined above, no FLC sample
qualifies as ‘‘hypermethylated’’. Applying the cases-specific defini-
tion of hypermethylation (‘‘50% more than in the paired normal
tissue’’, see above), 4/17 (23.5%) qualify as ‘‘hypermethylated’’ in
the GSTp1 gene.
Since the APC gene and the GSTp1 gene were found to be
hypermethylated in 60% (6/10 cases each) of common HCC
differences between FLC and HCC groups were significantly
different (p=0.0009 for both genes, Fisher’s exact test, two-sided).
Global methylation level in FLC
Global loss of methylation is well described for many solid
tumors and also for hepatocellular carcinoma [21]. Therefore, the
methylation level of LINE-1 sequences, highly repetitive DNA
elements scattered throughout the human genome, was assessed
using quantitative pyrosequencing. The methylation level of these
elements correlates very well with the global methylation level of
the genome under study and therefore can serve as surrogate
marker for the overall methylation level [12]. In comparison to
adjacent non-neoplastic liver tissue, no significant demethylation
of LINE-1 sequences was found in FLCs, indicating the absence of
widespread hypomethylation in this liver tumor (Figure 3). In
contrast, in common HCC from non-cirrhotic liver samples a
significant decrease of LINE-1 methylation in comparison to
adjacent non-neoplastic liver tissue was identified (p,0.0001,
Figure 3). The LINE-1 methylation level in the non-neoplastic
liver tissue from both patient groups (FLC and HCC) did not show
any differences (81.6+/27% versus 79.1+/27%, p=0.26, M-
Whitney-U, two-tailed).
Cluster analysis of methylation data
Unsupervised clustering of all quantitative log-transformed
methylation data revealed a very good separation of the FLC
samples from the HCC samples (Figure 4). Within these two
patient groups the separation between tumor and adjacent non-
neoplastic tissue is less pronounced (see Figure S2). The
clustering shown in Figure 4 underlines the distinct methylation
profile of FLC in comparison to common HCC arising in non-
cirrhotic liver already apparent from Figure 2.
Figure 3. Global methylation level in FLC and HCC without
cirrhosis. The Methylation level of LINE-1 sequences was measured
quantitatively using pyrosequencing. The Methylation level of these
repetitive elements reflects very well the overall methylation level of the
genome [12].
doi:10.1371/journal.pone.0013688.g003
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This is the first study that uses high-resolution quantitative
methodology for comparison of gene-specific and global DNA
methylation patterns of a large series of FLCs (n=15) with those in
common HCC arising in non-cirrhotic liver. Interesting differ-
ences between these two entities were revealed.
FLCs frequently harbor gene-specific hypermethylation in the
absence of global hypomethylation. For several loci the frequency
of aberrant hypermethylation is indistinguishable from conven-
tional hepatocellular carcinoma arising in the non-cirrhotic liver,
whereas for the APC and the CDH1 gene statistically significant
differences in hypermethylation could be found.
These data demonstrate that global reduction in DNA
methylation and gene-specific hypermethylation appear to repre-
sent independent events during tumor evolution of FLCs. These
observations are in accordance with studies focusing on common
hepatocellular carcinoma [22] and also other epithelial tumors
(e.g. prostate carcinoma [23] or urothelial carcinoma [24]), which
also show that global and gene-specific hypermethylation are
independent events. The data also demonstrate that full-blown
malignancy (i.e., carcinoma) can develop in the absence of global
hypomethylation.
Our results are also in line with the data from Kim et al. [25],
who showed that in common HCC global hypomethylation can
take place independent from cirrhosis.
The less distinct separation of FLC from adjacent tissue and
HCC from adjacent tissue, respectively, supports the concept of
‘‘field cancerization’’ [26], which involves epigenetic field defects
also in the non-neoplastic tissue adjacent to full-blown malignancy.
One FLC case was HBV positive (no. 13) and one common
HCC case was HCV positive (no. 10). But in both cases careful
reanalysis of all methylation data did not reveal any peculiarity in
comparison to the hepatitis-negative cases (see also Figure S1).
The results presented in this study are partly at variance with
another study of DNA methylation in a series of 5 FLCs describing
low levels of methylation in all FLCs without any difference in
comparison to adjacent non-neoplastic liver tissues [27]. We found
unequivocal and frequent hypermethylation of several loci (e.g.,
hsa-mir-9-1, hsa-mir-9-2, cyclinD2, RASSF1A) as well as total absence
of hypermethylation of the CDH1 (E-cadherin) gene. By contrast,
the CDH1 gene is reported by Vivekanandan and Torbenson to be
methylated in 4/4 normal liver samples and 5/5 FLC and 4/3
FLC metastases. In part, these discrepancies can be explained by
selection of genes. microRNA genes and the APC gene were not
included by Vivekanandan and Torbenson. However, the most
likely reason is difference in detection methodology: Vivekanan-
dan and Torbenson used exclusively conventional qualitative
methylation-specific PCR (MSP). From Figure 1 in their
publication it can be deduced that they scored any sample
showing a PCR product using M-primers as ‘‘methylated’’,
regardless of band intensity and ratio between M- and U-band.
This explains for example the occurrence of 100% methylation
of the CDH1 gene in normal liver samples and the inability to
detect differences in methylation levels between tumor specimens
and adjacent non-neoplastic liver tissue. Employing the very same
MSP primers for the analysis of all FLC specimens a weak ‘‘M-
band’’ of variable intensity relative to the corresponding ‘‘U-band’’
was observed for 7 tumor and 6 adjacent tissue samples (see Figure
S3).
Several groups (including our own) have demonstrated the
importance of employing quantitative methods in studying
aberrations in DNA methylation [6,28,29]. A mere qualitative
analysis is not able to identify highly significant differences
between tumor and surrounding tissue as well as between different
tumor types.
Conclusions
The results presented demonstrate the presence of frequent
aberrant DNA methylation in fibrolamellar carcinoma. However,
these differences were only discernible employing quantitative
methodology. In comparison to common HCC arising in non-
cirrhotic liver clear differences exist, separating these morpholo-
gically and clinically distinct entities also on the epigenetic level.
The aberrant hypermethylation in FLC specimens takes place in
the absence of a global loss of methylation, indicating that these
two epigenetic aberrations are well separated phenomena and that
full-blown malignancy can develop in the absence of global
hypomethylation.
Materials and Methods
Patient material
Cases of FLC (n=15) and HCC of non-cirrhotic liver (n=10)
from the period from 1988 to 2007 were retrieved from the
archive of the Institute of Pathology, Medizinische Hochschule
Hannover, Germany and analyzed anonymously. The local Ethics
committee (‘‘Ethik-Kommission der Medizinischen Hochschule
Hannover’’, head: Prof. Dr. Tro ¨ger) exempted this study from
review because all specimens under study were retrieved
anonymously and retrospectively (left-over samples from diagnos-
tic procedures) and waived the need for consent due to the fact the
samples received were anonymous. Age, sex, and TNM stage of
the tumors were extracted from the histological reports (see
Table 1). Clinical follow up data were not available. Cases were
independently reviewed by two diagnostic histopathologists (PF,
FP). Areas of tumor and non-tumor tissue were marked and DNA
was isolated from unstained serial sections using these marked
slides as guidance for manual microdissection.
DNA extraction and bisulfite treatment
Genomic DNA was isolated from formalin-fixed paraffin-
embedded specimens using proteinase K-digest over night
(50 mM Tris pH 8,1; 1 mM EDTA; 0,5% Tween 20; 10 mg/ml
proteinase K), followed by exhaustive organic extraction and
ethanol precipitation. Subsequently, DNA samples were treated
with sodium bisulfite using the EZ DNA Methylation Kit
TM
Figure 4. Cluster analysis of methylation data for FLC and
common HCC without cirrhosis. The quantitative methylation data
were log-transformed and translated into a color code.
doi:10.1371/journal.pone.0013688.g004
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the manufacturer’s instructions and finally eluted in 40 mL elution
buffer.
Generation of the PCR-products for methylation analysis
PCR products were generated in a 25 mL reaction volume with
400 nmol/L of forward, 40 nmol/L reverse and 400 nmol/L
universal biotinylated primers, 200 mmol/L of each dNTP,
1.5 mmol/L or 2.5 mmol/L MgCl2 (see Table 2 for all primer
sequences and reaction conditions), 16 Platinum-Taq reaction
buffer and 1.25 units PlatinumTaq
TM (Invitrogen, Karlsruhe,
Germany). PCR conditions were 95uC for 5 minutes, followed by
45 cycles with denaturation at 95uC for 30 seconds, annealing at
55uCo r6 0 uC (see Table 1) for 45 seconds, and elongation at 72uC
for 30 seconds finished with 1 cycle final elongation at 72uC for 5
minutes. The reverse primer is tagged by a sequence recognized by
the universal primer. Therefore, a single (expansive) biotinylated
primer can be used for all different gene-specific assays [30].
Methylation analysis using Pyrosequencing
PCR products (5–20 mL) were added to a mix consisting of 3 mL
Streptavidin Sepharose HP
TM (Amersham Biosciences, Freiburg,
Germany) and 37 mL binding buffer (Qiagen, Hilden, Germany)
and mixed at 1200 rpm for 5 minutes at room temperature.
Using the Vacuum Prep Tool
TM (Qiagen, Hilden, Germany),
single-stranded PCR products were prepared following the
manufacturer’s instructions. The sepharose beads with the single
stranded templates attached were released into a PSQ 96 Plate
Low
TM (Qiagen, Hilden, Germany) containing a mix of 12 mL
annealing buffer (Qiagen, Hilden, Germany) and 500 nmmol/L of
Table 2. Primer sequences.
Gene Forward primer MgCl2 [mM] TAnn [uC] Size (bp)
mir-9-1 f: GGG AAA TGG GGTATT AGA AAT TTT
r: [GGG ACA CCG CTG ATC GTT TA] CAA CAA CAA AAA CCT CAA ACA C
Pyro: TTT TTG GGT TTG GAT
1,5 60 140
mir-9-2 f: GGA AGA GAT GTT GAT TGA GAA AA
r: [GGG ACA CCG CTG ATC GTT TA] TAA TCA ACC AAC TAC CCC AC
Pyro: GGG ATT GTT GTA ATG TTG
1,5 60 114
APC f: GGA GAG AGA AGT AGT TGT GTA ATT T
r: [GGG ACA CCG CTG ATC GTT TA]A CTA CAC CAA TAC AAC CAC ATA TC
Pyro: TTA GGG TGT TTT TTA TTT T
2,5 55 123
CDH1 f: AGA TTT TAG TAA TTT TAG GTT AGA GG
r: [GGG ACA CCG CTG ATC GTT TA]C TAA TTA ACT AAA AAT TCA CCT ACC
Pyro a: ATT TTA GGT TAG AGG GTT AT
Pyro b: TTT GGG GAG GGG TT
1,5 55 134
Cyclin-D2 f: GTA TTT TTT GTA AAG ATA GTT TTG ATT
r: [GGG ACA CCG CTG ATC GTT TA] CCA AAC TTT CTC CCT AAA AAC
Pyro: ATA GTT TTG ATT TAA GGA TG
1,5 55 117
ESR1 f: GGY GAG GTG TAT TTG GAT AGT AG
r: [GGG ACA CCG CTG ATC GTT TA]C TAT TAA ATA AAA AAA AAC CCC C
Pyro: GTA TTT GGA TAG TAG TAA GTT
2,5 55 208
GSTp1 f: GGG GAG GGA TTA TTT TTA TAA G
r: [GGG ACA CCG CTG ATC GTT TA]A ATT AAC CCC ATA CTA AAA ACT CT
Pyro: GGA TTA TTT TTA TAA GGT
2,5 55 173
LINE-1 n/a (Qiagen) 1,5 50 n/a
MINT31 f: GTT TAG GGG TGA TGG TTT TAG
r: [GGG ACA CCG CTG ATC GTT TA]A AAC ACT TCC CCA ACA TC TAC
Pyro: GTG GTG ATG GAG GTT AT
1,5 55 188
RASSF1A f: AGT TTG GAT TTT GGG GGA GG
r: 59-Biotin-CAA CTC AAT AAA CTC AAA CTC CCC
Pyro: GGG TTY GTT TTG TGG TTT
1,5 60 136
SFRP1 f: TTG GGG ATT GYG TTT TTT GTT
r: [GGG ACA CCG CTG ATC GTT TA] ACT CTA CRC CCT ATT CTC C
Pyro: GAG GTT TTT GGA AGT TTG
1,5 55 108
SOCS1-a f: GTG AAG ATG GTT TYG GGA TTT
r: [GGG ACA CCG CTG ATC GTT TA]C AAC RAA ACC CCC AAC ATA C
Pyro: TTY GAG TTG TTG GAG TAT TA
1,5 55 150
SOCS1-b f: GTT TTT AGY GTG AAG ATG GTT T
r: [GGG ACA CCG CTG ATC GTT TA] CTA ACR AAA CAA CTC CTA CAA C
Pyro: GTT TTT ATT TGG ATG GTA G
1,5 55 221
univ-bio 59-Biotin-[GGG ACA CCG CTG ATC GTT TA]
Y=Pyrimidine (C/T).
R=Purine (A/G).
f=forward primer.
r=reverse primer.
Pyro=pyrosequencing primer.
Sequences in square brackets resemble universal tag for biotinylated primer.
doi:10.1371/journal.pone.0013688.t002
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TM reactions were performed in a PyroMark MD System
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions using the PyroGold SQA
TM Reagent Kit (Qiagen,
Hilden, Germany). CpG site quantification was performed using
the new methylation Software Pyro Q-CpG
TM.
Criteria for Pyrogram
TM selection were as follows: sufficient
peak height of .25 units for a single nucleotide (arbitrary units for
light emission calculated by the software), sharp symmetric peaks
without any irregularities or side-peaks, and a wide reading length
with a high reliability until the end of the sequence. Furthermore,
the absence of any significant signals at the positions where a
bisulfite treatment control was included or where control
nucleotides were dispensed to check for unspecific background
signals.
Methylation analysis using conventional Methylation-
specific PCR
For conventional qualitative methylation specific PCR the
primer pairs described by Vivekanandan and Torbenson were
used [27]. 20–50 ng bisulfite treated DNA were amplified using
0.5 units of Taq polymerase (Platinium Tag, Invitrogen, Karlsruhe
Germany) in the presence of 200 mM dNTPs, 1.5 mM MgCl2 and
10 pmol of each primer in the reaction buffer provided by the
manufacturer in a final volume of 25 ml. After an initial
denaturation of 2 min at 95uC, 40 cycles consisting of 30 sec at
95uC, 30 sec at 65uC and 40 sec at 72uC followed.
The PCR products were resolved on a 6% PAA gel and
visualized employing ethodium bromide staining.
Statistical analysis
Statistical differences were calculated using the Mann-Whitney-
U test. All calculations were performed using the software package
GraphPad Prism (version 5.01 for Windows, La Jolla, CA, USA).
p,0.05 were considered statistically significant.
For cluster analyses the quantitative methylation data from all
samples were log-transformed and uploaded into the statistical
package BRB array tool (version 3.5.0-Patch_2) [31]. Hierarchical
clustering was then performed applying Euclidean distance as a
dissimilarity metric and the complete linkage clustering method.
Supporting Information
Figure S1 Comparison of the two different definitions of
‘‘hypermethylated’’ (see ‘‘Results’’) if applied to all methylation
measurements performed in this study.
Found at: doi:10.1371/journal.pone.0013688.s001 (0.26 MB
TIF)
Figure S2 Separate clustering of methylation data for FLC and
adjacent non-neoplastic tissue (A) and common HCC from non-
cirrhotic liver and adjacent non-neoplastic tissue (B).
Found at: doi:10.1371/journal.pone.0013688.s002 (1.37 MB
TIF)
Figure S3 MSP results for three tumor/adjacent tissue sample
pairs using the primers described by Vivekanandan and
Torbenson. FLC7 shows a weak ‘‘M-band’’ in the adjacent tissue,
FLC8 in the tumor specimen and FLC4 in both fractions.
Altogether 7 tumor and 6 adjacent tissue specimens displayed an
‘‘M-band’’ of variable intensity relative to the corresponding ‘‘U-
band’’.
Found at: doi:10.1371/journal.pone.0013688.s003 (0.07 MB
TIF)
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